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ABSTRACT 54 
Background: Thymus transplantation is a promising strategy for the treatment of athymic 55 
complete DiGeorge syndrome (cDGS).  56 
Methods: Twelve patients with cDGS were transplanted with allogeneic cultured thymus.  57 
Objective: To confirm and extend the results previously obtained in a single centre. 58 
Results: Two patients died of pre-existing viral infections without developing thymopoeisis 59 
and one late death occurred from autoimmune thrombocytopaenia.  One infant suffered 60 
septic shock shortly after transplant resulting in graft loss and the need for a second 61 
transplant.  Evidence of thymopoeisis developed from 5-6 months after transplantation in 62 
ten patients. The median (range) of circulating naïve CD4 counts (x10
6
/L) were 44(11-440) 63 
and 200(5-310) at twelve and twenty-four months post-transplant and T-cell receptor 64 
excision circles were 2238 (320-8807) and 4184 (1582 -24596) per10
6 
T-cells. Counts did not 65 
usually reach normal levels for age but patients were able to clear pre-existing and later-66 
acquired infections. At a median of 49 months (22-80), eight have ceased prophylactic 67 
antimicrobials and five immunoglobulin replacement.  Histological confirmation of 68 
thymopoeisis was seen in seven of eleven patients undergoing biopsy of transplanted tissue 69 
including five showing full maturation through to the terminal stage of Hassall body 70 
formation. Autoimmune regulator (AIRE) expression was also demonstrated.  Autoimmune 71 
complications were seen in 7/12 patients. In two, early transient autoimmune haemolysis 72 
settled after treatment and did not recur. The other five suffered ongoing autoimmune 73 
problems including: thyroiditis (3); haemolysis (1), thrombocytopaenia (4) and neutropenia 74 
(1).  75 
Conclusions: This study confirms the previous reports that thymus transplantation can 76 
reconstitute T cells in cDGS but with frequent autoimmune complications in survivors. 77 
 78 
CLINICAL IMPLICATIONS 79 
Thymus transplantation should be the treatment of choice for infants with cDGS except 80 
possibly in those with severe pre-existing viral infections. The risk of autoimmune 81 
complications is a significant issue for survivors and further work is needed to understand 82 
this better.  83 
CAPSULE SUMMARY 84 
In twelve patients with complete DiGeorge syndrome treated with thymus transplantation, 85 
there was a 75% survival with T-cell reconstitution. Autoimmunity, mostly manageable, was 86 
a frequent occurrence in survivors. 87 
KEY WORDS 88 
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INTRODUCTION 91 
 92 
DiGeorge Syndrome with athymia, complete DiGeorge Syndrome (cDGS), results in a state 93 
of profound T cell deficiency.  The causal associations have been reviewed elsewhere[1]; 94 
DGS can be associated with a hemizygous microdeletion at chromosome 22q.11, CHARGE 95 
syndrome,  mutations in TBX1, deletions at chromosome 10p13-14 or fetal toxin exposure 96 
from glucose, ethanol or retinoic acid.  Around 1.5 % of children with 22q.11 deletion have 97 
the complete form of DiGeorge Syndrome [2] whereas the incidence of the problem in 98 
relation to other causes is unknown. The immunological phenotype is either of a profound 99 
T-cell lymphopenia or, in atypical cDGS, there may be oligoclonal expansions of memory 100 
phenotype T-cells conferring little or no protective immunity and causing inflammatory 101 
disease in the form of rashes, enteropathy and lymphadenopathy [3].  cDGS differs from 102 
severe combined immunodeficiency (SCID) in that the underlying defect  prevents 103 
development of the thymus whereas the underlying defect in SCID is a genetic defect in the 104 
hematopoietic lineage..  Patients with both cDGS and SCID, have a similar high risk of early 105 
death from infection. 106 
 107 
Two approaches have been used to correct the immunodeficiency in patients with cDGS.  108 
The first is T-cell replete haematopoietic stem cell transplantation (HSCT) but, because of 109 
the absence of thymus, this approach can only achieve engraftment of post-thymic T-cells.  110 
Whilst there are a number of reports of long lasting survival in patients treated in this way, 111 
particularly after matched sibling donor transplantation, the quality of the immune 112 
reconstitution achieved is poor [4]. Survival after  matched unrelated donor and matched 113 
sibling transplants were reported as being  33% and 60% respectively [5].   The alternative 114 
approach is to use thymus transplantation, which aims for a more complete reconstitution 115 
with ability to produce naïve T cells that show a broad T cell receptor (TCR) repertoire. 116 
Postnatal thymus tissue is readily available as it is routinely removed from infants 117 
undergoing open heart surgery through median sternotomy.  This approach has been used 118 
at a single centre in the United States since the mid-1990s.  There may have been some 119 
patient selection bias in the thymus transplanted group as patients suffering from severe co-120 
morbidities or with serious opportunistic infections were excluded. Nevertheless, the results 121 
compare very favourably with the outcome of HSCT with an approximately 75% long term 122 
survival in 60 patients[6]. Evidence of thymopoiesis and a diverse repertoire of naïve 123 
circulating T-cells, capable of HLA restricted specific antigen responses was seen in 124 
survivors. Non–survival in this cohort was mostly associated with pre-transplant morbidity, 125 
mainly viral infections and/or chronic lung disease [7]. Autoimmune hypothyroidism was 126 
relatively common at  just over 20% whilst an additional number of patients developed this 127 
problem pre-transplantation [6].  More serious and potentially life threatening 128 
autoimmunity including immune cytopaenias and enteropathy was also reported though 129 
much less commonly. The reasons for the occurrence of these complications are ill-130 
understood[8]. 131 
 132 
In order to test whether the technology could be successfully translated from the single 133 
centre and to make this treatment approach more readily available in Europe, a centre for 134 
thymus transplantation was established in London to provide this treatment for patients in 135 
Europe.  This report outlines the results of the first 12 patients treated with more than 24 136 
months of follow up. 137 
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 138 
METHODS 139 
 140 
PATIENTS 141 
Patients were recruited between 2009 -2014. In order to qualify for the study, those with 142 
typical cDGS had a maximum T-cell count of 50 x10
6
/L, no naïve T-cells and absent 143 
proliferative response to phytohaemagglutinin (PHA) response.  Atypical cDGS patients had 144 
less than 5% naïve CD4 cells (CD45 RA
+
, CD27
+
 or CD45 RA
+
, CD62L
+
). In addition there had to 145 
be at least one feature of the following:  congenital heart disease, hypoparathyroidism, 146 
hemizygosity for 22q.11 deletion or CHARGE syndrome. For further patient details see 147 
Online Repository.  148 
Patients with typical cDGS, without clonal expansions were not given any 149 
immunosuppression.  In those with atypical cDGS, CyclosporinA (CSA) was used pre-150 
transplantation to control inflammatory disease and this was continued post- 151 
transplantation.  These patients were also treated with three doses of rabbit anti-thymocyte 152 
globulin (ATG, Genzyme) 2 mg/kg body weight, Methylprednisolone 2 mg/kg intravenously 153 
for four days followed by oral prednisolone 1mg/kg for five days. 154 
 155 
 156 
OBTAINING, CULTURING AND TRANSPLANTING DONOR THYMUSES 157 
For details, including screening of donors, and the transplant procedure which has been 158 
described previously [9] see Online Repository. To assess cellular composition changes 159 
during the period of culture, separate thymuses were cultured specifically for analysis. For 160 
detailed methods see Online Repository  161 
 162 
 163 
 164 
LABORATORY ANALYSIS 165 
Flow cytometric analysis, mitogen responsiveness and measurement of T-cell receptor 166 
signal joint excision circle (TREC) levels involved standard methods described in the Online 167 
Repository. Testing for possible donor T cell engraftment using short tandem repeats 168 
utilised a method previously described [10] 169 
Clonality of T cells was assessed using T-cell receptor V beta chain spectratyping on the CD3 170 
positive population as previously described [11]. Regulatory T cell (Treg) numbers were 171 
measured on the CD4 population using CD25 and CD127 and intracellular staining for FoxP3. 172 
Spectratyping was also performed on Treg  populations purified by cell sorting based on 173 
CD4+, CD25 Hi, CD127 – cells and compared to the remaining CD4 cells. For assessment of 174 
Treg function, total CD4+  cells  were isolated and FoxP3 cells studied for CTLA4 175 
upregulation and transendocytosis of CD80  based on a previously reported method [12] 176 
modified by running the assay for  a period of 21 rather than 16 hours and by 177 
fixing/permeabilising the cells to allow staining for total CTLA4 rather than cycling surface 178 
CTLA4.  179 
The frequency of interferon-gamma (IFN-γ)-producing cells in response to either an 180 
autologous or third party EBV-transformed lymphoblastoid cell line (LCL)-specific 181 
stimulation was assessed on peripheral blood mononuclear cells (PBMC) using an ELISPOT 182 
assay, as previously reported [13] 183 
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Histological studies were performed on formalin fixed tissue  including  184 
immunohistochemical analysis by standard methods or as described previously [14] . Details 185 
of the antibodies used are given in the Online Repository. 186 
 187 
ETHICS 188 
The study was approved by the Institute of Child Health and Great Ormond Street Hospital 189 
Research Ethics Committee covering both thymus donation, including screening of the 190 
donors, and the transplant procedure in the recipient. Culture of thymus was undertaken 191 
under a licence from the UK Human Tissue Authority. 192 
 193 
 194 
RESULTS 195 
 196 
PATIENTS 197 
Details of the patients, including the genetic defect, comorbidities and infections acquired 198 
pre-transplantation are shown in Table I.  Median age at transplantation was 10 (range 2.5-199 
26) months. In two cases, the molecular basis of the DGS was undefined though, 200 
subsequently, in one of these a putative mutation has been found in TBX1 (analysis 201 
performed by Prof Klaus Schwartz, University of Ulm, Germany). Neither of these cases was 202 
an infant of a diabetic mother.  Atypical cDGS cases outnumbered typical in a ratio of 2:1.   203 
There was no evidence of Bacillus Calmette Guerin (BCG) -associated disease in the two 204 
recipients of this vaccine. Two patients had hypothyroidism before transplantation, the 205 
cause of which was not established. Both had negative tests for thyroid peroxisomal 206 
antibodies. One had a low TSH suggesting a possible central cause whilst in the other the 207 
problem proved to be transient. No patients had clear cut autoimmune disease prior to 208 
transplantation. 209 
 210 
THYMUS CULTURES 211 
During the period of thymic culture there was progressive lymphoid cell depletion and 212 
reciprocal increase in the proportion of EpCam positive TEC cells (Figure 1 a-c). A small 213 
fraction of T cells remained with a predominance of single positive CD4 cells (Figure 1 d) 214 
which could be induced to activate and to proliferate (Figure 1 e-f).  Histological sections of 215 
thymus slices before and after culture confirmed lymphoid depletion though some 216 
persisting lymphoid cells could be seen. There was preservation of a “network” of 217 
epithelium seen on cytokeratin staining with CK5 and CK14, staining predominantly 218 
medullary thymic epithelium (mTEC), and with CK8 staining both mTEC and cortical thymic 219 
epithelium (cTEC) (Figure E1 in the Online Repository, CK14 data not shown).  220 
 221 
CLINICAL OUTCOMES  222 
The surgical procedure was well tolerated in all patients. There were no wound infections or 223 
problems with wound healing.  The “dose” of thymus transplanted ranged between 8-18 224 
g/m
2 
BSA. 225 
Of the eight patients with atypical cDGS, all received CSA but three did not receive ATG 226 
because of concerns over potential worsening of pre-existing viral infections.  One patient 227 
(P11) with atypical cDGS additionally received two courses of Alemtuzumab to control 228 
inflammatory features within 3 months prior to transplantation. 229 
 230 
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Nine of the 12 patients are alive at median follow up time of 49 months (range 21-80 231 
months).  Two patients (P7 and P12) died at eight months and two weeks respectively after 232 
transplantation from pre-existing viral infections: disseminated cytomegalovirus (CMV) and 233 
parainfluenza 3 pneumonitis respectively. ATG had been withheld in both of these.  One 234 
further patient died of cerebral haemorrhage associated with immune thrombocytopaenia 235 
at 23 months post-transplantation. In P1, a first thymus graft failed to survive and she 236 
received a second successful graft after 12 months. More clinical detail of this case is given 237 
in the Online Repository.  238 
Clinical outcomes in survivors have generally been good with exceptions mainly from 239 
autoimmune problems or other non-immunological aspects of DGS (Table II). All developed 240 
thymopoeisis as evidenced by detection in the blood of naïve T cells with TRECs, with or 241 
without additional evidence from biopsies showing the features of thymopoeisis. 242 
 243 
 244 
Skin rashes 245 
Three patients, P1 (after 2
nd
 transplant), P2 and P6, developed skin rashes early (3-6 weeks) 246 
after transplant. They underwent skin biopsy which showed a non-specific dermatitis similar 247 
to the spongiotic dermatitis previously described in these cases.  No donor DNA could be 248 
detected in the skin or blood in any of these patients. 249 
 250 
Infections cleared 251 
Patients were able to clear a range of infectious agents after transplantation including those 252 
present before and those acquired after transplantation (Table II). Both cases receiving BCG 253 
vaccine prior to transplantation developed a localised severe inflammatory response at the 254 
inoculation site and in regional lymph nodes as T cell reconstitution occurred.  In patient 3, a 255 
primary EBV infection occurred 15 months after transplantation. He was able to clear this 256 
infection though low level EB viraemia persisted for 18 months before clearing.  P2, on 257 
chronic immunosuppression, managed to clear a number of virus infections. 258 
 259 
Autoimmunity 260 
Some form of autoimmune complication occurred in seven of the ten patients surviving to 261 
12 months (Table II). This took one of two forms, a very early onset before evidence of T cell 262 
immune reconstitution or an onset at or after T cell reconstitution. More detail of the 263 
autoimmune/inflammatory complications in each patient are provided in the Online 264 
Registry (Table E1). Two cases (P4, P9) were in the early onset category, both with 265 
haemolytic anaemia which responded to treatment and did not recur.  In five other patients, 266 
autoimmune problems, occurring at or after the time of T cell reconstitution, comprised 267 
mainly cytopaenias and/or thyroiditis. The latter was associated with the presence of anti-268 
thyroid peroxisomal (TPO) antibodies. A number of other transient autoimmune 269 
/inflammatory phenomena also occurred in some patients at or soon after immune 270 
reconstitution. It was not possible to identify any association between the development of 271 
autoimmunity and any methodological factors including the choice of thymus donor, 272 
thymus culture medium used, amount of tissue transplanted or use of ATG conditioning.  Six 273 
of the ten patients surviving to 12 months had partial HLA matching at 1-5 loci at 4-digit 274 
resolution typing (Table EII in Online Repository). The three patients without any 275 
autoimmune complications all fell in to this group but three others, also with some 276 
matching, developed autoimmunity though in one of these this was just a transient early 277 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
haemolysis. All patients without any HLA matching developed autoimmunity (one with 278 
transient early haemolysis only). A trend towards less autoimmunity in the presence of 279 
some HLA matching was not statistically significant (Fisher’s exact test). 280 
 281 
 282 
IMMUNOLOGICAL TESTING POST TRANSPLANTATION 283 
 284 
 T cell Immunity 285 
Donor leukocyte engraftment was not detected in any of the patients. Circulating T-cell 286 
numbers in surviving patients rose from around 5 months and naïve T cells from around 6-7 287 
months after transplantation (Figure 2). The correlation between naïve cell numbers using 288 
different flow cytometric strategies is shown in the Online Registry (Figure E2). Cell numbers 289 
achieved, generally, did not reach the normal age-related range (Table E III in the Online 290 
Repository). There was a continuing rise in naïve cell numbers up to 24 months and then 291 
maintenance at a relatively steady level. Low numbers of T cells in P2 were likely due to 292 
immunosuppression.  No other patients received long term immunosuppression. Numbers 293 
of TRECs showed a similar time course to naïve T cells (Figure 3a). There was a relatively 294 
poor correlation between TRECs and naïve CD4 and CD8 cells (Figure E3 in the Online 295 
repository). Normal TCR diversity by V beta spectratyping of CD3 cells was achieved in seven 296 
patients, including those with atypical cDGS and an abnormal spectratype pre-297 
transplantation (Figure E4 in the Online Repository). An abnormal spectratype persists in 298 
three patients (P2 P6 and P9). Further analysis showed a normal CD4 spectratype in P6 299 
whilst both CD4 and CD8 spectratypes were abnormal in P9. Mitogen responsiveness to PHA 300 
(Figure 3b) improved in all patients but fell again with the immunosuppression in P2.  For 301 
unknown reasons, it never normalised in P1. . This patient had good evidence for 302 
thymopoeisis on biopsy and blood analysis.Following primary EBV infection, peripheral 303 
blood mononuclear cells from Patient 3 showed the ability to produce a good interferon 304 
gamma (IFN γ) response against an autologous EBV transformed lymphoblastoid cell line 305 
(LCL) but responded significantly  less well  to a third party LCL (Figure 3c). Phenotyping of 306 
circulating cells with markers of Tregs was performed in five patients (P2,P4,P6,P9,P10 )and 307 
showed these cells to be present in low absolute numbers though when expressed as the 308 
proportion of CD4 cells  there was no difference to a healthy age- range matched control 309 
group (Figure 4a&b and Figure E5 in the Online Repository). In P2, P4, P6, P9 the proportions 310 
of CD45RA positive Tregs was 6,32,8 and 44 % respectively, whilst in the controls the 311 
median level was 67 (range 27-94). The functional ability of CD4+ Foxp3+ cells  in six 312 
patients (P2,4,5,6,8,9) in terms of CTLA4 upregulation upon activation and transendocytosis 313 
of CD80 was comparable to adult control samples ( Figure 4 c &d and Figures E6 &7 in the 314 
Online Repository). In P9, spectratyping performed on sorted Treg cells showed a diverse 315 
repertoire  (Figure E8 in the Online Repository). 316 
 317 
There was no correlation found between the level of immunological reconstitution achieved 318 
and factors relating to the choice of thymus donor, thymus culture medium used, amount of 319 
tissue transplanted or the use of ATG conditioning. 320 
 321 
B cell immunity 322 
All patients were on immunoglobulin replacement prior to transplantation. Five patients 323 
stopped immunoglobulin at around 24 months post-transplant as per the protocol and have 324 
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normal IgG levels. To date, five patients have been immunised against tetanus toxoid and 325 
show protective responses. Three received conjugate pneumococcal vaccine and two of 326 
these have made good protective responses. One patient failed to respond to this vaccine 327 
and is being re-immunised.  IgA levels were undetectable before transplant in 11/12 328 
patients and low (0.1g/L) in the other. The levels have normalised after transplant in all 329 
survivors with the exception of P2.  330 
B cell numbers  remained normal (Figure E9a in the Online Repository) in all patients except 331 
those (P2, 4)receiving treatment with anti CD20 monoclonal antibody (rituximab) The 332 
proportion of CD19+ B cells which were CD27+ IgD- (class switched memory B, CSMB, cells)  333 
was tested in 9 patients. It remained relatively low compared to published age related 334 
controls [15] in some patients whereas in others it was within normal limits particularly 335 
after two years. (Figure E9b in Online Repository)   336 
 337 
THYMIC BIOPSIES 338 
Biopsies of up to four transplanted thymic slices were undertaken on 11 patients (including 339 
one after each transplant in P1) at a median time of 4 months (range 2-8 months) after 340 
transplantation. Areas of histologically normal thymic tissue were seen in the muscle, 341 
including cortico-medullary distinction and Hassall body formation in 5 biopsies. In these 342 
biopsies immunohistochemical staining showed abundant T (CD3+) cells with evidence of 343 
cortical thymopoeisis, as defined by the expression of TdT, CD1a and Ki67, and of normal 344 
maturation to the late medullary thymic epithelial (mTEC) stage defined by the expression 345 
of CK5 and CK14, Claudin 4, AIRE and involucrin.Foxp3 staining showed frequent positive 346 
cells present (Fig 5 and Figure E10 in Online Repository). Biopsies in a further two cases 347 
(P8,P9) showed less well developed thymic architecture but definite evidence of cortical  348 
thymopoeisis as defined by the presence of CD1a and Ki67 positive cortical thymocytes (not 349 
shown).  Biopsies with no evidence of thymopoeisis were found in P1 (first transplant), 2, 5 350 
and 7. In P 2 & 5 it was likely the biopsies “missed” thymus in the muscle as there was later 351 
appearance of thymic emigrants in the blood indicating thymopoeisis. In P7 who died of 352 
CMV, a biopsy taken at four months showed viable thymic epithelium but very little 353 
thymopoeisis (Figure E11a-d in Online Repository)). CMV could not be demonstrated in this 354 
thymic tissue (not shown). P12 died very early after transplant and a post mortem 355 
examination of transplanted thymus revealed viable epithelium with extensive 356 
neovascularisation (Figure E11 e-f in Online Repository). 357 
 358 
 359 
 360 
 361 
 362 
DISCUSSION 363 
 364 
This study shows that transplantation of cultured thymic epithelium can reconstitute T cell 365 
immunity in patients with complete DiGeorge syndrome enabling them to control 366 
opportunistic infections and to have a quality of life not restricted by susceptibility to 367 
infection. This confirms and adds to the results in the previously reported series [6, 7], with 368 
the survival rate and the level of immune reconstitution achieved being similar between the 369 
two series. The proportion of children suffering autoimmune complications is higher in the 370 
present study but as numbers are relatively small it is difficult to know if this difference is 371 
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significant.  In the present study, novel data documenting changes in the cellular 372 
composition of thymus slices during culture are provided as well as data on TREC levels 373 
achieved and numbers, phenotype and function of Tregs. There is also detailed histological 374 
evidence on thymic biopsies to confirm full maturation of mTEC. Whilst all but one of the 375 
patients in this study had a recognised genetic cause for DGS, the previous studies included 376 
a number of such cases, including those with maternal diabetes, and showed that such 377 
patients have an equivalent outcome. 378 
 379 
The levels of T cell reconstitution achieved in surviving patients were not usually normal for 380 
age but were sufficient to allow clearance of viral and other infections.  In most cases, 381 
normal mitogen responsiveness was achieved and a diverse repertoire was demonstrated 382 
on TCR spectratyping.  Circulating Tregs could be detected in proportions similar to control 383 
children though at lower absolute numbers and their CTLA4 mediated function was shown 384 
to be normal. . Apart from one case in which an IFN γ response to EBV was shown, antigen 385 
specific T cell responses were not assayed in this study. Such responses were studied to 386 
tetanus and candida antigens in the previous series and showed positive responses in all but 387 
one of the surviving patients [7]  Most patients with follow up of more than two years have 388 
been able to stop immunoglobulin and, in those tested so far, all show normal antibody 389 
responses to tetanus and two of three to conjugated pneumococcal vaccine. IgA deficiency 390 
corrected in all but one patient. The numbers of class switched memory B cells remains 391 
relatively low in some patients, but in order to assess the significance of this finding longer 392 
follow up is needed to see if the proportions rise with time. The reasons for the suboptimal 393 
numbers of T cells achieved in most patients is not clear. It could be that insufficient thymus 394 
tissue was transplanted but against this is the fact that there was no correlation in this study 395 
or in the North American series [8]  between the  amount of tissue transplanted and the 396 
eventual T cell or naïve T cell  counts achieved. Neither was there any association between 397 
counts and the type of medium used for culture, the use of ATG nor the presence of chance 398 
overlap of HLA antigens between donor and recipient.  399 
We have shown here that the cultured thymus loses most of its lymphoid cell populations 400 
during culture and is relatively enriched for thymic epithelial cells (TECs). However, viable 401 
lymphoid cells capable of proliferation are still present. These cells may be necessary for the 402 
maintenance and growth of the TECs[16]. Theoretically, these cells could mediate graft 403 
versus host disease but this was not seen and, on blood analysis, engraftment of donor 404 
haematopoietic cells was not detected in any patient. One situation where thymopoeisis 405 
may not develop is in the context of pre-existing cytomegalovirus (CMV) infection as seen in 406 
P7 in this study and in the previous studies [7, 17]. The finding of viable thymic epithelium 407 
but no thymopoeisis on biopsy is consistent with the possibility that this virus, the agents 408 
used to treat it or both may inhibit the development of thymopoeisis. Children with cDGS 409 
complicated by CMV infection did not survive in either this or the previous study.  410 
Biopsy of transplanted thymus has been shown to be helpful in determining whether 411 
thymopoeisis is developing[17]. In that report biopsies were done at around two months 412 
post-transplantation. The positive ones all showed  evidence of cortical  thymopoeisis but, in 413 
over half, no thymic medulla or Hassalls corpuscles were seen[17]. In the present study, 414 
biopsies were done later (median 4 months). In most of those that were positive there was 415 
clear cortico-medullary differentiation as well as development of Hassalls corpuscles with 416 
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immunohistochemical evidence that differentiation of mTEC proceeds to the terminal 417 
stages. It is likely that the difference in timing of the biopsies accounted for these 418 
differences between this and the previous series. 419 
 420 
 In the present and previous series, autoimmune complications were relatively common, 421 
predominantly involving thyroiditis and cytopaenias. Some of these complications were of a 422 
transient nature which may reflect immune dysregulation during T cell reconstitution 423 
sometimes seen in other clinical situations such as after HSCT and in experimental models 424 
[18].  Two very early cases of autoimmunity were seen before any T cell emergence and 425 
could conceivably have had nothing to do with the transplant.  426 
The reasons for the susceptibility to autoimmune complications are poorly understood. The 427 
possibility that inadequate negative selection by non-MHC matched mTEC contributes to 428 
the development of autoimmunity was not supported by the finding in this and the previous 429 
larger study [8] of no beneficial effect of chance, partial HLA matching.  430 
 In conclusion, this study has strengthened the case for thymus transplantation being the 431 
corrective treatment of choice for complete DiGeorge syndrome, offering the possibility of 432 
immune reconstitution to a degree that will give a quality of life not limited by infection 433 
susceptibility. Autoimmunity, a common complication, can often be managed relatively 434 
easily but a proportion of children can suffer serious consequences. Further work is required 435 
to understand better the pathogenesis of this problem.  As newborn screening programmes 436 
for SCID expand, more patients may require this treatment. Further work is needed to 437 
streamline the labour-intensive process requiring specialised facilities for generating and 438 
transplanting thymus. A model of human thymus transplantation into the nude mouse may 439 
be useful in further exploring this [19]. Other patients who might benefit from this approach 440 
include SCID infants who fail to immune reconstitute after HSCT or gene therapy because of 441 
thymic insufficiency.  442 
 443 
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Table I – Patient Characteristics 504 
 505 
Patient/Gender/Age 
at transplant 
(months) 
Diagnosis  CD3 (naïve) 
 x 10
6/L 
Other problems & infections present 
at the time of transplantation 
1. Female, 14  & 26* 
 
CHARGE (CHD7) Typical 
20 (0) 
Atrioventricular Canal, Hypoparathyroidism
Recurrent Sepsis, Non-specific enteropathy
Previous  B cell lymphoma 
HHV6 
2.Male, 8  22q.11.2 deletion Typical 
30 (0) 
Fallots Tetralogy, Hypoparathyroidism
C.difficile  
3. Male, 18  CHARGE (CHD7) Atypical 
1200 (0) 
Choanal atresia –Tracheostomy, 
Bilateral facial nerve palsy, 
Small ventricular septal defect (closed spontaneously), 
Chronic lung disease (colonised with 
4. Male, 26 CHARGE (CHD7) Atypical 
800 (0) 
Truncus arteriosus, Nephrocalcinosis
Chronic lung disease,  
enteropathy, Rotavirus  
5. Male, 9  Undefined Typical 
30 (0) 
Truncus arteriosus, Hypoparathyroidiism
Not dysmorphic, BCG, Rotavirus 
 6. Male,10 CHARGE (CHD7) Atypical 
650 (0) 
Fallots Tetralogy, Hypoparathyroidism
Chronic enteropathy, Norovirus 
7. Male, 4+ 22q.11.2 deletion Atypical 
1470 (0) 
Patent ductus, Bronchomalacia, 
Hypoparathyroidism, CMV  
8. Male,  5  22q.11.2 deletion  Atypical 
350 (0) 
Recurrent aspiration, Hypoparathyroidism
Ventricular septal defect (closed spontaneously), 
Patent foramen ovale 
9. Male, 16  Undefined (Putative 
Mutation in TBX1 
Atypical (mild) 
120 (2) 
Recurrent sepsis, Mastoiditis, Hypoparathyroidism,
Hypothyroidism BCG, Rotavirus, RSV, 
10. Female 2.5 + 22q.11.2 deletion  Typical 
0 
Truncus arteriosus Aortic incompetence
Hypoparathyroidism, Hypothyroidism
Recurrent pneumonia 
11. Male, 5  22q.11.2 deletion Atypical 
1250 (40) 
Hypoparathyroidism, 
Asymptomatic Coronavirus  
12. Male, 14 + 22q.11.2 deletion  Atypical 
370 (0) 
Hypoparathyroidism, chronic lung disease,
Parainfluenza 3, Rotavirus 
Footnotes: * two transplants; 
+ 
these patients subsequently died after transplantation 506 
BCG – Bacillus Calmette Guerin, CMV – Cytomegalovirus, RSV – Respiratory syncytial virus 507 
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Table II - Clinical outcome in patients surviving beyond 12 months 508 
 509 
 510 
Patient 
Follow up 
(months) 
Infections cleared 
(bold if present pre- 
transplantation) 
Autoimmunity Attending School/ 
Pre-school 
Significant
Ongoing 
Treatments
1. 69 
(after second 
transplant) 
HHV6 Transient nephritis 
Thyroiditis 
YES Thyroxine 
2. 80 C. difficile, RSV 
Adenovirus+ 
Enterovirus, Varicella 
Parainfluenza 3 
Norovirus,Rhinovirus 
Transient colitis 
Chronic  AIHA 
ITP 
YES 
 
Splenectomy.
Sirolimus 
Iron Chelation
IG replacement
3.M, 67 RSV, Parainfluenza 3 
Metapneumovirus, 
EBV (primary) 
None YES 
 
Azithromycin 
prophylaxis
Tracheostomy  
decanulated
4.M, 55 Rotavirus 
Parainfluenza 3 
Metapneumovirus, 
RSV, Influenza A 
Early transient AIHA YES 
 
Azithromycin 
prophylaxis
5.M,  49 mo BCG, Rotavirus 
Parainfluenza 3 
None YES 
 
Azithromycin 
prophylaxis
6.M, 46 Norovirus 
 
None YES Ig therapy 
Cleft lip/palate repair
8. M 30 Rhinovirus, RSV Thyroiditis 
ITP, Neutropenia 
YES Gastrostomy feeding
Thyroxine 
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9. M 25 BCG, Rotavirus, RSV Early transient AIHA NO On Ig therapy
Thyroxine 
10. F 23 HHV6, Adenovirus ITP – Fatal at 23 months 
post-transplant 
NO On Ig therapy
Thyroxine 
11. M 21 Coronavirus, C.difficile 
Campylobacter 
Thyroiditis 
ITP 
Elevated transaminases 
 
 
YES On Ig therapy
Thyroxine 
 511 
Footnotes:  512 
+ 
-1x10
5 
copies/ml of blood 513 
 AIHA – Autoimmune haemolytic anaemia; BCG – Bacillus Calmette –Guerin; EBV – Epstein 514 
Barr virus; HHV6 – Human herpes virus 6;  Ig – Immunoglobulin ; ITP – Immune 515 
thrombocytopaenia; RSV – Respiratory syncytial virus; 516 
 517 
 518 
 519 
 520 
 521 
 522 
 523 
 524 
 525 
  526 
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Legends to Figures: 527 
1. Analysis of cellular composition of thymus slices by flow cytometry at different 528 
time points during culture. a. Dot plots show representative anti-CD45 versus EpCam 529 
1 staining. The percentages of EpCam1+CD45- cells are given in the regions shown. 530 
Histograms show anti-HLA DR staining gated on the EpCam1+ CD45- population 531 
shown in the dot plots. b. Number of live cells recovered showing the overall 532 
number of thymocytes and the number ofCD4/CD8 double positive (DP) thymocytes 533 
retrieved per mg of tissue. c. The percentage of cells that were CD45-EpCam1+HLA-534 
DR+ (as frequency of live gate). d. Proportion of cells in each thymocytesubset (SP, 535 
single positive; DP, double positive; DN, double negative) based on CD4 and CD8 536 
surface expression. e. When stimulated for 5 days, thymocytes from day 15 slices 537 
proliferate. f. When stimulated for 72hours, CD4 single positive thymocytes from day 538 
22 slices upregulate the activation marker, CD25 539 
2. T cell reconstitution after transplantation.  Dotted lines indicate 10
th
 percentile of 540 
published lymphocyte subset counts in normal children aged 1-2 years and 2-5 years 541 
[20].  542 
3. a. TREC levels performed on CD3 cells with 10
th
 percentile for in-house normal 543 
ranges for children of <2 years and 2-5 years. b. PHA responses – maximum counts 544 
per minute after stimulation of isolated mononuclear cells stimulated with 545 
phytohaemagglutinin. Dotted line indicates the 10
th
 percentile for  in-house normal 546 
adult controls c. Frequency of interferon gamma producing cells in patient’s 547 
peripheral blood mononuclear cells (PBMC) measured by ELISPOT (mean ± SEM) in 548 
response to autologous and third party EBV transformed lymphoblastoid cell lines in 549 
P3 Following primary Epstein Barr virus infection. Two-tailed Student’s t-test for 550 
unpaired samples was applied.   551 
1) 4. a & b. Cells with T regulatory phenotype expressed as percentage of CD4 cells  and 552 
in absolute numbers in patients (n=5) and an age-range matched control group 553 
(n=11). c. & d. Transendocytosis assay shows CD4 + FOXP3+ cells in patients (n=6) 554 
and controls (n=5) incubated with anti CD3 plus untransfected Chinese Hamster 555 
ovary (CHO) cells, or with anti CD3 plus CHO transfected with CD80 with or without 556 
anti-CTLA4. c. Upregulation of CTLA4 expression (shown as mean fluorescence 557 
intensity , MFI, of Tregs normalised to MFI of CTLA4 in that individual’s own naïve 558 
conventional T cells (as internal negative control). Panel d. Relative total 559 
fluorescence intensity of CD4+ Foxp3 + cells that have acquired GFP tagged onto 560 
CD80 as a result of transendocytosis of CD80.  This is derived from MFI of GFP 561 
multiplied by the number of GFP positive cells to get total fluorescence intensity, 562 
divided by number of Tregs acquired. In both panels, the patients and controls 563 
showed equivalent results.  564 
 565 
5. Histological appearances of positive thymic biopsies.  a & b. haematoxylin & eosin 566 
showing medullary differentiation and Hassall body formation. Original 567 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
18 
 
magnification 10x and 40x respectively. c. expression of Foxp3 within thymic medulla 568 
(brown). Original magnification 20x. d. Double staining with TdT (brown, nuclear 569 
signal) showing immature thymocytes within the cortical area and CD3 (blue, 570 
membrane signal) highlighting maturing T lymphocytes within the medulla (Original 571 
magnification 40x).e. AIRE expressing cells within medullary region (original 572 
magnification 20x) f. Double staining for AIRE (brown) and Involucrin (blue) that 573 
shows co-localization of AIRE expressing cells with fully mature involucrin expressing 574 
mTEC (original magnification 40x).  575 
 576 
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